TCL-1B4 Activators
TCL-1B4 Activators encompass a variety of chemical compounds that indirectly enhance the functional activity of TCL-1B4 through distinct biochemical pathways. Forskolin, known for its capacity to increase intracellular cAMP levels, activates Protein Kinase A (PKA), which in turn phosphorylates key substrates in signaling pathways involving TCL-1B4. This activation amplifies TCL-1B4's activity, particularly in pathways where cAMP and PKA are pivotal. Genistein, as a tyrosine kinase inhibitor, facilitates the enhancement of TCL-1B4's activity by reducing the competitive influence of tyrosine kinase signaling, allowing pathways involving TCL-1B4 to be more prominently active. Inhibitors of the PI3K/AKT pathway, such as LY294002 and Wortmannin, contribute to TCL-1B4's functional enhancement by altering the dynamics of cellular responses where TCL-1B4 plays a role, particularly in processes governed by the PI3K/AKT pathway.
Moreover, the functional activity of TCL-1B4 is further influenced by compounds that modulate MAPK signaling. The MEK inhibitors U0126 and PD98059 shift signaling dynamics in favor of TCL-1B4-involved pathways, particularly by impacting the MAPK/ERK pathway, thereby indirectly enhancing TCL-1B4's activity. Similarly, SB203580 and SP600125, which inhibit p38 MAPK and JNK respectively, play a role in TCL-1B4 activation by diminishing competitive signaling in these pathways, thus indirectly promoting TCL-1B4's involvement. Compounds like Thapsigargin and A23187, which affect calcium signaling, enhance TCL-1B4's activity by triggering calcium-dependent pathways, crucial in processes where TCL-1B4 is involved. Lastly, Rapamycin, through its inhibitory effect on mTOR, impacts interconnected pathways and processes, leading to an indirect enhancement of TCL-1B4's functional activity. These compounds collectively facilitate the enhancement of TCL-1B4's roles in various cellular processes, emphasizing their indirect yet pivotal influence on TCL-1B4's functional enhancement.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin, by elevating intracellular cAMP levels, indirectly enhances TCL-1B4's functional activity by activating Protein Kinase A (PKA). PKA then phosphorylates substrates that are crucial in signaling pathways in which TCL-1B4 is involved, leading to its enhanced activity. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein, a tyrosine kinase inhibitor, indirectly augments the functional role of TCL-1B4 by reducing competition from tyrosine kinase signaling. This allows pathways involving TCL-1B4 to be more active, thereby enhancing its function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a PI3K inhibitor, indirectly influences TCL-1B4 activity by modulating the PI3K/AKT pathway. This leads to altered cellular responses in which TCL-1B4 plays a role, thereby enhancing its functional activity. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine, a broad-spectrum protein kinase inhibitor, can indirectly enhance TCL-1B4 activity by lifting the inhibition exerted by specific kinases on TCL-1B4-related processes. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126, a MEK1/2 inhibitor, indirectly enhances TCL-1B4 activity by shifting signaling equilibria in pathways where TCL-1B4 is involved, notably by affecting the MAPK/ERK pathway. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin increases intracellular calcium levels, thereby activating calcium-dependent signaling pathways crucial for processes in which TCL-1B4 is involved, leading to its enhanced activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059, a MEK inhibitor, indirectly enhances TCL-1B4 activity by modulating the MAPK pathway, which in turn influences cellular processes involving TCL-1B4. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580, a p38 MAPK inhibitor, alters signaling pathways that indirectly enhance TCL-1B4's functional role by reducing competitive signaling and thus facilitating TCL-1B4 pathway activation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, indirectly enhances the activity of TCL-1B4 by influencing signaling pathways where JNK is a competitive or regulatory element, thus indirectly facilitating TCL-1B4 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, another PI3K inhibitor, similarly to LY294002, indirectly enhances TCL-1B4 activity by affecting the PI3K/AKT pathway and subsequent cellular processes where TCL-1B4 is involved. | ||||||